jRCT2080223008UnknownPhase 3
Efficacy and safety trial of AJG533 in patients with chronic constipation (Phase 3 study)
Conditions
Trial Snapshot
- Phase
- Phase 3
- Sponsor
- EA Pharma Co.,Ltd.
- Enrollment
- 120
- Primary Endpoint
- -
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Intervention Model
- Placebo controlled, randomized, double blind, multicenter, parallel group design
Eligibility Criteria
- Ages
- 20age old over to No limit (—)
- Sex
- All
Inclusion Criteria
- •<Main inclusion criteria>
- •Patients with chronic constipation
Exclusion Criteria
- •<Main exclusion criteria>
- •Patients with known or suspected organic constipation
- •Patients with known or suspected symptomatic constipation or drug-induced constipation
Outcomes
Primary Outcomes
-
Frequency of Spontaneous Bowel Movement Change from baseline
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Completed
Phase 3
Phase 3 study of AJG555 in patients with chronic constipationChronic constipationjRCT2080223112EA Pharma Co., Ltd.140
Unknown
Phase 3
Long term study of AJG533 in patients with chronic constipationChronic constipationjRCT2080223007EA Pharma Co.,Ltd.360
Unknown
Phase 3
Phase III study of AJG511 in patients with active ulcerative colitisulcerative colitisJPRN-jRCT2080222653EA Pharma Co.,Ltd.120
Unknown
Phase 3
Phase 3 study of AJG533 in patients with chronic constipatioChronic constipationJPRN-jRCT2080223008EA Pharma Co.,Ltd.120
Unknown
Phase 2
Dose-finding study of AJG533 in patients with chronic constipation (Phase 2 study)Chronic constipationJPRN-jRCT2080222557AJINOMOTO PHARMACEUTICALS CO.,LTD.